$84.92-2.23 (-2.56%)
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories.
IRADIMED CORPORATION in the Healthcare sector is trading at $86.21. The stock is currently 20% below its 52-week high of $107.90, remaining 0.5% above its 200-day moving average. Technical signals show neutral RSI of 33 and bearish MACD signal, explaining why IRMD maintains its current momentum and trend strength. The Whystock Score of 95/100 reflects a high-conviction bullish alignment.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers ...
Companies in The News Are: NWL,CL,EL,IRMD
iRadimed Corp (IRMD) reports a 13% revenue increase and robust demand for its new MR IV pump system, despite production challenges.
Yet again, it posted growth and robust profitability in its latest quarter.
iRadimed (NASDAQ:IRMD) reported second-quarter 2025 results that management said marked the company’s 16th consecutive quarter of record revenues, driven by strength in its MRI-compatible infusion pump business and continued growth in patient monitoring. For the quarter ended June 30, 2025, revenue
iRadimed (IRMD) delivered earnings and revenue surprises of +8.89% and +1.61%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?